List of Excipients in Branded Drug WEZLANA

WEZLANA Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Wezlana (ustekinumab-auub) is Amgen’s biosimilar and interchangeable product to Stelara (ustekinumab). Its commercial value comes from access to a large immunology market, interchangeable status, a familiar subcutaneous presentation, and potential payer-driven substitution. The excipient strategy is deliberately conservative: Wezlana uses a conventional protein formulation with histidine buffering, sucrose stabilization, polysorbate 80 surfactant, and water for injection. The strongest opportunities are in manufacturing reliability, device usability, supply economics, contracting, and lifecycle extensions rather than aggressive excipient differentiation.

What is Wezlana and which excipients does it contain?

Wezlana is a monoclonal antibody biosimilar to ustekinumab, the active ingredient in Stelara. The FDA approved Wezlana in October 2024 for the same major indications as Stelara, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It is approved as an interchangeable biosimilar, subject to the statutory requirements governing pharmacy-level substitution and state law.[1]

Wezlana formulation composition

The FDA prescribing information identifies the following inactive ingredients:

Component	Formulation role
L-histidine	Primary buffer component
L-histidine monohydrochloride monohydrate	Buffer capacity and pH control
Sucrose	Tonicity and protein stabilization
Polysorbate 80	Surfactant and interface protection
Water for injection	Vehicle

The product is a sterile, preservative-free solution for subcutaneous administration. Wezlana is supplied in 45 mg/0.5 mL and 90 mg/1.0 mL presentations, including prefilled syringe and vial configurations identified in the product labeling.[1]

The formulation is designed to maintain ustekinumab stability during refrigerated storage and administration. It does not rely on a novel excipient or a formulation concept that would create a separate product category.

Why does the Wezlana excipient strategy matter commercially?

The excipient package affects product quality, comparability, manufacturing yield, shelf life, tolerability, and supply-chain cost. For a biosimilar, the commercial objective is usually to reduce formulation risk rather than maximize formulation novelty.

A conventional excipient system provides four commercial advantages:

1. It supports analytical comparability with the reference product.
2. It reduces the probability that formulation changes create new immunogenicity concerns.
3. It simplifies regulatory justification for multiple strengths and devices.
4. It supports manufacturing at commercial antibody concentrations without adding an untested excipient.

The principal tradeoff is limited differentiation. Histidine, sucrose, and polysorbate 80 are widely used in injectable biologics. Competitors can use similar excipient systems, leaving device design, contracting, supply continuity, and administration services as more practical differentiators.

How does Wezlana’s formulation compare with Stelara?

Wezlana is required to be highly similar to Stelara, but the FDA does not require an identical inactive-ingredient profile. The commercial significance of any formulation difference depends on its effect on product quality, safety, immunogenicity, pharmacokinetics, and clinical performance.

Attribute	Wezlana	Stelara
Active ingredient	Ustekinumab-auub	Ustekinumab
Product class	Interchangeable biosimilar	Reference biologic
Administration	Subcutaneous injection; intravenous induction for selected gastrointestinal indications under product labeling	Subcutaneous injection; intravenous induction for selected gastrointestinal indications
Key stabilizer	Sucrose	Sucrose-based formulation
Buffer system	Histidine-based	Histidine-based
Surfactant	Polysorbate 80	Polysorbate 80
Preservative	None	None
Commercial position	Lower-cost biosimilar with interchangeability	Originator biologic
Primary differentiation	Price, contracting, access, supply, device execution	Established brand, physician familiarity, clinical history

The broad excipient alignment reduces the risk that physicians or payers view Wezlana as clinically or administratively distinct from Stelara. It also limits the possibility of excipient-related switching objections.

What formulation risks are associated with Wezlana’s excipients?

Polysorbate 80 degradation

Polysorbate 80 is widely used in monoclonal antibody products but can undergo oxidation and hydrolysis. Degradation may generate subvisible particles, free fatty acids, or other species that affect product appearance and protein stability.

Manufacturing controls should monitor:

• Polysorbate concentration over shelf life
• Oxidative degradation products
• Subvisible and visible particles
• Protein aggregation
• Fragmentation and charge variants
• Container-closure interaction
• Agitation and shipping sensitivity

The risk is material because prefilled syringes expose the formulation to repeated handling, silicone oil, and possible contact with container surfaces.

Histidine buffer performance

Histidine is commonly used for biologics because it provides buffering in an acidic-to-near-neutral range and can support protein stability. The control strategy must maintain pH within the validated range throughout manufacturing, storage, and administration.

pH drift can influence:

• Aggregation
• Deamidation
• Oxidation
• Charge heterogeneity
• Injection-site tolerability
• Subcutaneous absorption

The formulation’s commercial benefit is familiarity. Its limitation is that histidine buffer does not create a meaningful exclusivity barrier.

Sucrose concentration and osmolality

Sucrose acts as a stabilizer and contributes to tonicity. Changes in sucrose concentration can affect osmolality, viscosity, freeze-thaw behavior, and protein conformational stability. The formulation must also remain compatible with the intended syringe and vial materials.

Protein concentration and viscosity

The 90 mg/mL presentation creates a balance between dose convenience and injectability. Higher concentration can reduce injection volume but increase viscosity and force requirements. These factors affect:

• Manual syringe use
• Autoinjector compatibility
• Injection duration
• Patient adherence
• Device selection
• Home-administration acceptance

For Wezlana, viscosity and delivery force are commercial issues because the product competes in chronic inflammatory diseases where patients may self-administer treatment for years.

What formulation patents protect Wezlana?

Wezlana is protected primarily through biologic product regulation, manufacturing know-how, trade secrets, and Amgen’s rights under the biosimilar patent-resolution process. The excipient combination itself is unlikely to provide broad, durable protection because histidine, sucrose, and polysorbate 80 are established pharmaceutical ingredients.

Does Wezlana have Orange Book-listed patents?

No. The Orange Book covers approved drug products, including small-molecule products and certain drug-device combinations, but biologic reference products such as Stelara are generally tracked through the FDA’s Purple Book rather than the Orange Book.[2]

Patent and exclusivity analysis for Wezlana should therefore distinguish among:

• Stelara composition and antibody patents
• Stelara formulation patents
• Stelara manufacturing-process patents
• Method-of-treatment patents
• Device and container-closure rights
• Biosimilar litigation settlements
• Regulatory exclusivity and interchangeability status

The absence of an Orange Book listing does not mean that the product lacks patent barriers. It means the applicable biologic framework is different.

When did Stelara lose regulatory exclusivity, and when could biosimilar competition begin?

Stelara received FDA approval in 2009. The 12-year period of reference-product exclusivity for a biologic expired before the main wave of ustekinumab biosimilar launches. Patent settlements and negotiated launch dates, rather than regulatory exclusivity alone, determined the practical timing of competition.

Amgen announced that Wezlana would launch in the United States under a settlement arrangement with Johnson & Johnson and Janssen. The settlement permitted a U.S. launch beginning January 1, 2025, subject to the agreement’s terms.[3]

Key exclusivity and launch timeline

Date	Event
September 2009	FDA approval of Stelara
September 2021	Approximate end of 12-year reference-product exclusivity
2023-2024	Ustekinumab biosimilar patent settlements and regulatory approvals
October 2024	FDA approval of Wezlana
January 1, 2025	Announced U.S. Wezlana launch date under settlement terms
2025 onward	Expansion of payer, provider, specialty-pharmacy, and substitution competition

Which companies are challenging Stelara’s market position?

The U.S. ustekinumab market is moving from single-brand dominance toward multi-biosimilar competition. The competitive group includes Amgen, Sandoz, Celltrion, Teva and other developers pursuing or commercializing ustekinumab biosimilars across jurisdictions.

Company	Product or program	Competitive relevance
Amgen	Wezlana, ustekinumab-auub	FDA-approved interchangeable biosimilar
Sandoz	Pyzchiva, ustekinumab-ttwe	FDA-approved biosimilar; U.S. commercialization opportunity
Celltrion	Otulfi, ustekinumab-aekn	FDA-approved biosimilar
Teva and partners	Selarsdi, ustekinumab-aauz	U.S. biosimilar competitor
Johnson & Johnson/Janssen	Stelara	Reference product and originator

The practical competitive question is not whether one biosimilar can enter. It is how many suppliers will receive preferred formulary status and whether payers use a multi-source tender model.

What is Wezlana’s FDA regulatory status?

Wezlana is FDA-approved as a biosimilar and interchangeable biosimilar to Stelara. The interchangeable designation may support pharmacy substitution where permitted by state law and payer policy, but it does not guarantee automatic substitution in every jurisdiction or product setting.

The designation has commercial value because it can reduce friction in payer and specialty-pharmacy channels. It is most relevant in self-administered subcutaneous maintenance therapy, where prescription routing and product substitution can materially influence market share.

The intravenous induction use for Crohn’s disease and ulcerative colitis requires separate operational planning. Hospitals and infusion centers may apply different formulary, purchasing, and substitution processes than retail or specialty pharmacies.

How strong is the Wezlana patent estate?

The product’s formulation patent strength is moderate to limited if assessed solely on the disclosed excipients. The stronger barriers are regulatory complexity, manufacturing capability, analytical characterization, supply reliability, and the cost of biosimilar development.

Patent-strength assessment

Protection category	Relative strength	Commercial assessment
Active antibody sequence	High for originator-era claims, subject to expiration and validity	Ustekinumab sequence rights created the primary historic barrier
Broad excipient combination	Low to moderate	Ingredients are established and difficult to monopolize broadly
Specific concentration or pH range	Moderate	May support narrower claims if technically differentiated
Manufacturing process	Moderate to high	Process parameters and know-how can be difficult to replicate
Device and packaging	Moderate	Can delay copying of a delivery system but rarely blocks all market entry
Regulatory interchangeability	High commercial value	Supports substitution but is not a patent right
Trade secrets and quality systems	High practical value	Important for yield, consistency, and cost

Amgen’s advantage is therefore more likely to rest on regulatory approval, manufacturing scale, launch timing, and contracting than on a broad excipient patent monopoly.

What commercial opportunities does Wezlana create?

Payer contracting and formulary access

The largest opportunity is price-based access. Payers can use Wezlana to negotiate rebates against Stelara and competing biosimilars. Amgen can offer a contracting package tied to:

• Interchangeable status
• Supply guarantees
• Specialty-pharmacy distribution
• Patient support
• Reduced medical and pharmacy benefit costs
• Coverage across dermatology, rheumatology, gastroenterology, and infusion channels

A lower wholesale acquisition cost alone may not secure market share. Net price, rebate structure, inventory reliability, and payer administration will determine access.

Device-led differentiation

Because the excipient system is conventional, the delivery device is a practical differentiation route. Opportunities include:

• Lower injection force
• Shorter injection time
• Larger grip surfaces
• Improved needle shielding
• Autoinjector compatibility
• Reduced preparation steps
• Packaging designed for cold-chain handling
• Patient-use instructions tailored to chronic self-administration

Device changes can create new regulatory and IP workstreams. They can also generate switching friction if a payer or specialty pharmacy standardizes around one presentation.

Manufacturing and supply-chain optimization

Wezlana’s excipients are commercially available and widely used, reducing raw-material novelty risk. Procurement strategy should focus on polysorbate 80 quality, low-peroxide specifications, supplier qualification, lot consistency, and dual sourcing.

Key manufacturing opportunities include:

• Higher-yield cell culture and purification
• Reduced hold times
• Lower aggregate formation
• Improved sterile filtration recovery
• Reduced filling losses
• Optimized syringe and vial line utilization
• Lower cold-chain costs
• Global batch harmonization

These improvements can have a greater effect on margin than a change in excipient identity.

Geographic expansion

The product can support different commercial strategies by region. The United States emphasizes interchangeability, payer substitution, and patent-settlement timing. Europe places greater weight on national reimbursement, tendering, biosimilar adoption policies, and country-level substitution rules.

A globally consistent formulation may reduce supply-chain complexity, but regional packaging, labeling, device, and reimbursement requirements can still require market-specific configurations.

What generic-entry risks exist for Wezlana?

Wezlana faces biosimilar competition rather than conventional generic competition. The main risks are:

1. Multiple interchangeable or substitutable ustekinumab biosimilars competing on net price.
2. Payer exclusion or preferred formulary placement for another supplier.
3. Physician reluctance to switch stable patients.
4. Specialty-pharmacy inventory constraints.
5. Manufacturing deviations involving aggregation, particles, or polysorbate degradation.
6. Device usability problems in home administration.
7. State-level differences in substitution rules.
8. Contracting pressure that compresses biosimilar margins.
9. Separate procurement dynamics for intravenous induction.
10. Additional international competitors with lower production costs.

The highest commercial risk is a multi-source price war. Once several products have comparable regulatory status and clinically familiar excipient systems, the buyer can prioritize net cost and supply assurance.

What litigation and settlement issues affect Wezlana?

Ustekinumab biosimilar entry has been shaped by patent litigation and settlement agreements between biosimilar developers and Johnson & Johnson or Janssen. The settlements can establish launch dates, geographic rights, royalty structures, and restrictions affecting specific presentations or indications.

For Wezlana, the announced January 1, 2025 U.S. launch date is commercially important because it converts patent-resolution terms into a defined market-entry window.[3] The settlement does not eliminate all legal risk. Follow-on disputes can still involve:

• Manufacturing patents
• Device patents
• Labeling and method-of-use claims
• Patent-term calculations
• Royalty obligations
• International launch timing
• Competition-law scrutiny of settlement terms

A complete diligence review should separate litigation concerning Stelara from litigation concerning Wezlana’s own manufacturing, device, or distribution activities.

What is the revenue exposure associated with Stelara biosimilars?

Stelara generated approximately $10.9 billion in worldwide sales in 2023, according to Johnson & Johnson’s annual reporting.[4] The U.S. market is the main near-term commercial target because of high biologic spending, specialty-pharmacy concentration, and the potential effect of interchangeability.

Revenue exposure will depend on:

• U.S. versus international sales mix
• Speed of payer adoption
• Share of patients switched from Stelara
• Net price erosion
• Number of biosimilar competitors
• Hospital versus pharmacy benefit utilization
• Crohn’s disease and ulcerative colitis adoption
• Continuity of originator rebates
• Amgen’s production cost and contracting discipline

For Amgen, Wezlana can extend biosimilar scale in immunology. For Johnson & Johnson, biosimilar erosion is likely to be managed through Stelara contracting, lifecycle positioning, and migration to newer immunology products.

How does Wezlana compare with competing ustekinumab biosimilars?

Wezlana has a strong initial position because of its interchangeable designation and Amgen’s commercial infrastructure. Its formulation is unlikely to be the primary source of differentiation.

Commercial factor	Wezlana position
Regulatory status	FDA-approved interchangeable biosimilar
Excipient differentiation	Limited
Device opportunity	Meaningful
Manufacturing scale	Supported by Amgen capabilities
Payer leverage	Strong potential, dependent on net pricing
Physician adoption	Supported by reference-product familiarity
Litigation exposure	Controlled by settlement-based launch framework
Margin risk	High if multiple suppliers receive preferred status
International opportunity	Dependent on country reimbursement and tender rules

Key Takeaways

• Wezlana is an FDA-approved interchangeable biosimilar to Stelara.
• Its excipient system uses histidine, histidine hydrochloride monohydrate, sucrose, polysorbate 80, and water for injection.
• The formulation strategy prioritizes comparability, stability, and manufacturing reliability over novel excipient protection.
• Polysorbate 80 degradation, aggregation, particles, viscosity, and device compatibility are the principal technical risks.
• The product is not evaluated through an Orange Book patent listing; Stelara and Wezlana are governed primarily through the biologic and Purple Book framework.
• Amgen’s commercial opportunity is concentrated in interchangeable substitution, payer contracting, supply reliability, device execution, and specialty-pharmacy access.
• The main competitive threat is multi-source biosimilar price erosion rather than a conventional generic challenge.
• Stelara’s large revenue base creates a substantial market opportunity, but sustained margins will depend on contracting discipline and manufacturing cost.

FAQs

Does Wezlana contain citrate?

The FDA label identifies histidine-based buffering, sucrose, polysorbate 80, and water for injection. Citrate is not identified as an inactive ingredient in the labeled formulation.[1]

Can Wezlana be automatically substituted for Stelara?

Interchangeability supports substitution under applicable law, but pharmacy substitution depends on state requirements, payer policy, product channel, and prescription circumstances.

Are Wezlana’s excipients patentable?

Individual excipients such as histidine, sucrose, and polysorbate 80 are established ingredients. Narrow claims covering concentration, pH, stability, particle control, or a specific device may be possible, but the basic excipient combination is unlikely to create broad exclusivity.

Can Wezlana be used for intravenous induction in inflammatory bowel disease?

Wezlana labeling includes the applicable ustekinumab induction and maintenance regimens for Crohn’s disease and ulcerative colitis. Administration requirements differ between intravenous induction and subcutaneous maintenance and must follow the approved label.[1]

What is the main investment risk for Wezlana?

The principal risk is rapid price compression from several ustekinumab biosimilars competing for preferred payer and specialty-pharmacy placement. Formulation risk is manageable but remains relevant to supply continuity, shelf life, device performance, and manufacturing cost.

References

1. U.S. Food and Drug Administration. (2024). Wezlana (ustekinumab-auub) prescribing information.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
3. Amgen Inc. (2024). Amgen announces U.S. FDA approval of Wezlana (ustekinumab-auub), a biosimilar to Stelara.
4. Johnson & Johnson. (2024). 2023 annual report.